ArticleEULAR rheumatology open2026
Learning to live with RA as an unwelcome companion-patients' experiences after 1 to 2 years of DMARD treatment.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Rheumatoid arthritis (RA) can be life-changing, requiring long-term treatment to control disease activity. It is therefore important to gain knowledge about patients' experiences of living with RA after 1 to 2 years of disease-modifying antirheumatic drug (DMARD) treatment. Methods: This qualitative study used an inductive approach. Interviews were conducted with 22 patients with RA in 7 focus groups (17 participants) and 5 individual interviews. Participants were 15 women and 7 men, with a median age of 57 years, an RA disease duration of 12 to 21 months, and 12 to 20 months of treatment with conventional synthetic or biological DMARDs. The interviews were analysed using qualitative content analysis. Results: Patients' experiences of living with RA after 1 to 2 years of DMARD treatment reflected a recognition of RA as an unwelcome companion that the patients had learned to live with. The experiences were expressed as: (i) managing daily life despite disease limitations, including struggling with work-life balance and trying to maintain social participation; (ii) reconfiguring the self with disease limitations through feeling unlike oneself, and experiencing changes in bodily appearance and mood; (iii) finding humility despite disease limitations by being grateful for the treatment and making the most of each day. Conclusions: After 1 to 2 years of DMARD treatment, participants experienced RA as an unwelcome companion, with daily life constrained by physical, psychological, and social demands. Care should therefore extend beyond inflammation control to include person-centred, goal-oriented support and rehabilitation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.